Compare AXGN & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 126.2M |
| IPO Year | N/A | 2000 |
| Metric | AXGN | AGEN |
|---|---|---|
| Price | $31.16 | $3.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $33.67 | $14.50 |
| AVG Volume (30 Days) | ★ 1.1M | 454.3K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $214,709,000.00 | $106,829,000.00 |
| Revenue This Year | $21.57 | $67.15 |
| Revenue Next Year | $15.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $9.22 | $1.38 |
| 52 Week High | $34.24 | $7.34 |
| Indicator | AXGN | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.72 | 34.22 |
| Support Level | $28.98 | $3.82 |
| Resistance Level | $30.76 | $4.12 |
| Average True Range (ATR) | 1.64 | 0.19 |
| MACD | -0.28 | -0.06 |
| Stochastic Oscillator | 56.21 | 0.23 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).